Alteration of N‐glycan profiles in patients with chronic hepatitis and hepatocellular carcinoma

Most of the modification of N‐glycosylation reported in cancers including hepatocellular carcinoma (HCC) were based on the examinations of a small number of patients or particular proteins. The aim of this study is to reveal changes in whole serum N‐glycan profiles systematically during the process of hepatocarcinogenesis and to elucidate their clinical application.

[1]  Shinichiro Nakamura,et al.  Serum glycan as a prognostic marker in patients with advanced hepatocellular carcinoma treated with sorafenib , 2014, Hepatology.

[2]  S. Nishimura,et al.  Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis , 2013, Hepatology.

[3]  H. Shiraha,et al.  Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer , 2013, Journal of Gastroenterology.

[4]  Lijuan Hu,et al.  The role of N-acetylglucosaminyltransferases V in the malignancy of human hepatocellular carcinoma. , 2012, Experimental and molecular pathology.

[5]  W. Alley,et al.  N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. , 2012, Journal of proteome research.

[6]  V. Simonyan,et al.  N-glycans in liver-secreted and immunoglogulin-derived protein fractions. , 2012, Journal of proteomics.

[7]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[8]  J. Marrero,et al.  Recent advances in the treatment of hepatocellular carcinoma , 2010, Current opinion in gastroenterology.

[9]  J. Michalski,et al.  Modifications of human total serum N‐glycome during liver fibrosis–cirrhosis, is it all about immunoglobulins? , 2010, Proteomics. Clinical applications.

[10]  C. Van Steenkiste,et al.  Alteration of protein glycosylation in liver diseases. , 2009, Journal of hepatology.

[11]  N. Hayashi,et al.  IgG Oligosaccharide Alterations Are a Novel Diagnostic Marker for Disease Activity and the Clinical Course of Inflammatory Bowel Disease , 2008, The American Journal of Gastroenterology.

[12]  N. Hayashi,et al.  A high expression of GDP-fucose transporter in hepatocellular carcinoma is a key factor for increases in fucosylation. , 2007, Glycobiology.

[13]  R. Contreras,et al.  N‐glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus , 2007, Hepatology.

[14]  Terence C W Poon,et al.  Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach. , 2006, Journal of proteome research.

[15]  I. Witz,et al.  The involvement of selectins and their ligands in tumor-progression. , 2006, Immunology letters.

[16]  J. Kutok,et al.  Rolling of Human Bone-Metastatic Prostate Tumor Cells on Human Bone Marrow Endothelium under Shear Flow Is Mediated by E-Selectin , 2004, Cancer Research.

[17]  R. Kannagi,et al.  Carbohydrate‐mediated cell adhesion in cancer metastasis and angiogenesis , 2004, Cancer science.

[18]  M. Fiorentino,et al.  Expression of β-galactoside α2,6 sialyltransferase and of α2,6-sialylated glycoconjugates in normal human liver, hepatocarcinoma, and cirrhosis , 2003 .

[19]  T. Suda,et al.  N‐Acetylglucosaminyltransferase V as a possible aid for the evaluation of tumor invasiveness in patients with hepatocellular carcinoma , 2001, Journal of gastroenterology and hepatology.

[20]  Yasuyuki Arakawa,et al.  Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.

[21]  Takao Tsuji,et al.  New Inuyama classification; new criteria for histological assessment of chronic hepatitis , 1996 .

[22]  T. Suda,et al.  Microheterogeneity of serum transferrin in the diagnosis of hepatocellular carcinoma , 1996, Journal of gastroenterology and hepatology.

[23]  Y. Maeda,et al.  Alteration of asparagine-linked glycosylation in serum transferrin of patients with hepatocellular carcinoma. , 1994, Clinica chimica acta; international journal of clinical chemistry.

[24]  K. Tanikawa,et al.  A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. , 1993, Cancer research.

[25]  K. Taketa,et al.  Sugar chains of human cord serum alpha-fetoprotein: characteristics of N-linked sugar chains of glycoproteins produced in human liver and hepatocellular carcinomas. , 1993, Cancer research.

[26]  R. Groszmann,et al.  American association for the study of liver diseases , 1992 .

[27]  R. Purcell,et al.  Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus , 1990, Hepatology.

[28]  A. Kobata,et al.  Altered glycosylation of serum transferrin of patients with hepatocellular carcinoma. , 1989, The Journal of biological chemistry.

[29]  Y. Aoyagi,et al.  The reactivity of alpha-1-antitrypsin with Lens culinaris agglutinin and its usefulness in the diagnosis of neoplastic diseases of the liver. , 1987, British Journal of Cancer.

[30]  T. Ono,et al.  Fucosylation of serum α-fetoprotein in patients with primary hepatocellular carcinoma , 1985 .

[31]  D. Shafritz,et al.  Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. , 1981, The New England journal of medicine.

[32]  Shin-Ichiro Nishimura,et al.  Toward automated glycan analysis. , 2011, Advances in carbohydrate chemistry and biochemistry.

[33]  M. Fiorentino,et al.  Expression of beta-galactoside alpha2,6 sialyltransferase and of alpha2,6-sialylated glycoconjugates in normal human liver, hepatocarcinoma, and cirrhosis. , 2004, Glycobiology.

[34]  S. Pizzo,et al.  Potential pathogenicity of deglycosylated IgG cross reactive with streptokinase and fibronectin in the serum of patients with rheumatoid arthritis. , 1996, The Journal of rheumatology.

[35]  T. Ono,et al.  Fucosylation of serum alpha-fetoprotein in patients with primary hepatocellular carcinoma. , 1985, Biochimica et biophysica acta.